DRMA Stock Summary and Trading Ideas (Dermata Therapeutics | NASDAQ:DRMA)

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Dermata Therapeutics trades on the NASDAQ stock market under the symbol DRMA.

As of August 28, 2026, DRMA stock price declined to $1.34 with 95,392 million shares trading.

DRMA has a beta of 1.76, meaning it tends to be more sensitive to market movements. DRMA has a correlation of 0.07 to the broad based SPY ETF.

DRMA has a market cap of $6.64 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, DRMA traded as high as $21.60 and as low as $.57.

DRMA has underperformed the market in the last year with a price return of -75.0% while the SPY ETF gained +19.7%. DRMA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -0.7% and -8.2%, respectively, while the SPY returned +2.2% and -0.9%, respectively.

DRMA support price is $1.33 and resistance is $1.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRMA shares will trade within this expected range on the day.